pSivida (NASDAQ:PSDV) announced its earnings results on Wednesday, February 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02, Yahoo Finance reports. pSivida had a negative return on equity of 205.82% and a negative net margin of 882.37%. The firm had revenue of $0.93 million for the quarter, compared to analyst estimates of $0.48 million.
Shares of pSivida (NASDAQ PSDV) traded up $0.01 during trading on Thursday, hitting $1.07. The stock had a trading volume of 90,100 shares, compared to its average volume of 387,792. pSivida has a 1-year low of $0.93 and a 1-year high of $2.45. The firm has a market capitalization of $47.97, a P/E ratio of -1.83 and a beta of 1.27.
Several research firms have recently commented on PSDV. HC Wainwright set a $5.00 price target on pSivida and gave the stock a “buy” rating in a report on Thursday, February 8th. B. Riley set a $5.00 price target on pSivida and gave the stock a “buy” rating in a report on Friday, December 15th. Northland Securities reissued a “buy” rating and set a $10.00 price objective on shares of pSivida in a research report on Monday, December 11th. ValuEngine downgraded pSivida from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Laidlaw initiated coverage on pSivida in a research report on Wednesday, November 8th. They set a “buy” rating and a $5.00 price objective for the company. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. pSivida currently has a consensus rating of “Buy” and an average price target of $7.57.
WARNING: This article was first reported by Week Herald and is the property of of Week Herald. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://weekherald.com/2018/02/15/psivida-psdv-announces-quarterly-earnings-results.html.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.